Wells Fargo analyst Derek Archila raised the firm’s price target on C4 Therapeutics (CCCC) to $10 from $5 and keeps an Overweight rating on the shares. The firm thinks cemsidomide’s updated data at the 75ug and 100ug doses presented this weekend at the IMS meeting suggest better efficacy/safety than BMS programs and should allow for future combos in earlier-line MM. Wells thinks shares should trade up on the news.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCCC:
- C4 Therapeutics price target raised to $10 from $8 at Barclays
- C4 Therapeutics Reports Promising Phase 1 Trial Results
- C4 Therapeutics: Balancing Promise and Competition in the Multiple Myeloma Market
- C4 Therapeutics presents data from Phase 1 trial of cemsidomide
- C4 Therapeutics initiated with an Overweight at Barclays